Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial

Abstract

Minimal objective evidence exists regarding management of Friedreich’s ataxia (FRDA). Antioxidant and recombinant human erythropoietin therapies have been considered potential treatments to slow progression of FRDA in a small number of studies. The primary objective of the current study was to test the efficacy, safety, and tolerability of triple therapy… (More)
DOI: 10.1007/s12311-013-0482-y

Topics

1 Figure or Table

Cite this paper

@article{Arpa2013TripleTW, title={Triple Therapy with Darbepoetin Alfa, Idebenone, and Riboflavin in Friedreich’s Ataxia: an Open-Label Trial}, author={Javier Arpa and Irene Sanz-Gallego and Francisco J. Rodr{\'i}guez-de-Rivera and Francisco J. Dom{\'i}nguez-Melc{\'o}n and Daniel Prefasi and Javier Oliva-Navarro and Mar Moreno-Yang{\"{u}ela and Samuel Ignacio Pascual-Pascual}, journal={The Cerebellum}, year={2013}, volume={12}, pages={713-720} }